Heart Failure Clinical Trial
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Summary
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
Eligibility Criteria
Inclusion Criteria:
Men or women aged 18 years and older
Diagnosis of chronic heart failure (CHF), NYHA ( New York Heart Association ) class II-IV, LVEF ≤ 35% and elevated NT-proBNP
Exclusion Criteria:
Acute de-novo heart failure
Requirement of any intravenous (IV) treatments following 48 hours prior to randomization
Mechanical support (e.g. intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device)
Any cause of chronic heart failure other than ischemic cardiomyopathy and idiopathic dilated cardiomyopathy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 73 Locations for this study
Naples Florida, 34102, United States
Detroit Michigan, 48202, United States
Jackson Mississippi, 39216, United States
Saint Louis Missouri, 63136, United States
Kalispell Montana, 59901, United States
Stony Brook New York, 11794, United States
Youngstown Ohio, 44501, United States
Tullahoma Tennessee, 37388, United States
Houston Texas, 77002, United States
Brugge , 8000, Belgium
Gilly , 6060, Belgium
Roeselare , 8800, Belgium
Turnhout , 2300, Belgium
Pernik , 2300, Bulgaria
Pleven , 5800, Bulgaria
Sofia , 1233, Bulgaria
Sofia , 1527, Bulgaria
Sofia , 1618, Bulgaria
Veliko Tarnovo , 5000, Bulgaria
Hannover Niedersachsen, 30625, Germany
Bad Oeynhausen Nordrhein-Westfalen, 32545, Germany
Dortmund Nordrhein-Westfalen, 44137, Germany
Mönchengladbach Nordrhein-Westfalen, 41063, Germany
Ludwigshafen Rheinland-Pfalz, 67063, Germany
Berlin , 13353, Germany
Kifisia / Athens Attica, 14561, Greece
Athens , 11527, Greece
Elefsina , 19018, Greece
Nea Ionia / Athens , 142 3, Greece
Thessaloniki , 54642, Greece
Ashkelon , 78306, Israel
Hadera , 38101, Israel
Haifa , 31096, Israel
Jerusalem , 91031, Israel
Jerusalem , , Israel
Tel Aviv , 64239, Israel
Zrifin , 60930, Israel
Napoli Campania, 80131, Italy
Roma Lazio, 00168, Italy
Bergamo Lombardia, 24127, Italy
Brescia Lombardia, 25123, Italy
Milano Lombardia, 20138, Italy
Arezzo Toscana, 52040, Italy
Maebashi Gunma, 371-8, Japan
Takasaki Gunma, 370-0, Japan
Amagasaki Hyogo, 660-8, Japan
Higashiibaraki Ibaraki, 311-3, Japan
Naha Okinawa, 902-8, Japan
Kishiwada Osaka, 596-8, Japan
Takatsuki Osaka, 569-1, Japan
Hachioji Tokyo, 192-0, Japan
Itabashi-ku Tokyo, 173-8, Japan
Shinjuku-ku Tokyo, 162-8, Japan
Hiroshima , 734-8, Japan
Okayama , 702-8, Japan
Osaka , 558-8, Japan
Toyama , 930-8, Japan
Amsterdam , 1091 , Netherlands
Arnhem , 6815 , Netherlands
Groningen , 9700 , Netherlands
Rotterdam , 3015 , Netherlands
Bialystok , 15-77, Poland
Katowice , 40-15, Poland
Krakow , 31-12, Poland
Lodz , 91-30, Poland
Poznan , 61-84, Poland
Szczecin , 71-43, Poland
Wroclaw , 50-98, Poland
Santiago de Compostela A Coruña, 15706, Spain
El Palmar Murcia, 30120, Spain
A Coruña , 15006, Spain
Madrid , 28007, Spain
Madrid , 28040, Spain
Valencia , 46010, Spain
Valencia , 46026, Spain
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.